Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension

Liliana Moreno-Vinasco, Mardi Gomberg-Maitland, Michael L. Maitland, Ankit Desai, Patrick A. Singleton, Saad Sammani, Lee Sam, Yang Liu, Aliya N. Husain, Roberto M. Lang, Mark J. Ratain, Yves A Lussier, Joe GN Garcia

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Pulmonary hypertension (PH) and cancer pathology share growth factor- and MAPK stress-mediated signaling pathways resulting in endothelial and smooth muscle cell dysfunction and angioproliferative vasculopathy. In this study, we assessed sorafenib, an antineoplastic agent and inhibitor of multiple kinases important in angiogenesis [VEGF receptor (VEGFR)-1-3, PDGF receptor (PDGFR)-β, Raf-1 kinase] as a potential PH therapy. Two PH rat models were used: a conventional hypoxia-induced PH model and an augmented PH model combining dual VEGFR-1 and -2 inhibition (SU-5416, single 20 mg/kg injection) with hypoxia. In addition to normoxia-exposed control animals, four groups were maintained at 10% inspired O2 fraction for 3.5 wk (hypoxia/vehicle, hypoxia/SU-5416, hypoxia/ sorafenib, and hypoxia/SU-5416/sorafenib). Compared with normoxic control animals, rats exposed to hypoxia/SU-5416 developed hemodynamic and histological evidence of severe PH while rats exposed to hypoxia alone displayed only mild elevations in hemodynamic values (pulmonary vascular and right ventricular pressures). Sorafenib treatment (daily gavage, 2.5 mg/kg) prevented hemodynamic changes and demonstrated dramatic attenuation of PH-associated vascular remodeling. Compared with normoxic control rats, expression profiling (Affymetrix platform) of lung RNA obtained from hypoxia [false discovery rate (FDR) 6.5%]- and hypoxia/SU-5416 (FDR 1.6%)-challenged rats yielded 1,019 and 465 differentially regulated genes (fold change >1.4), respectively. A novel molecular signature consisting of 38 differentially expressed genes between hypoxia/SU-5416 and hypoxia/SU-5416/sorafenib (FDR 6.7%) was validated by either real-time RT-PCR or immunoblotting. Finally, immunoblotting studies confirmed the upregulation of the MAPK cascade in both PH models, which was abolished by sorafenib. In summary, sorafenib represents a novel potential treatment for severe PH with the MAPK cascade a potential canonical target.

Original languageEnglish (US)
Pages (from-to)278-291
Number of pages14
JournalPhysiological Genomics
Volume33
Issue number2
DOIs
StatePublished - Apr 22 2008
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Rodentia
Hemodynamics
Immunoblotting
sorafenib
Hypoxia
Proto-Oncogene Proteins c-raf
Platelet-Derived Growth Factor Receptors
Lung
Vascular Endothelial Growth Factor Receptor
Ventricular Pressure
Semaxinib
Antineoplastic Agents
Genes
Smooth Muscle Myocytes
Blood Vessels
Real-Time Polymerase Chain Reaction
Lung Neoplasms
Intercellular Signaling Peptides and Proteins
Phosphotransferases

Keywords

  • Bioinformatics
  • Microarrays
  • SU-5416

ASJC Scopus subject areas

  • Physiology
  • Genetics

Cite this

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. / Moreno-Vinasco, Liliana; Gomberg-Maitland, Mardi; Maitland, Michael L.; Desai, Ankit; Singleton, Patrick A.; Sammani, Saad; Sam, Lee; Liu, Yang; Husain, Aliya N.; Lang, Roberto M.; Ratain, Mark J.; Lussier, Yves A; Garcia, Joe GN.

In: Physiological Genomics, Vol. 33, No. 2, 22.04.2008, p. 278-291.

Research output: Contribution to journalArticle

Moreno-Vinasco, L, Gomberg-Maitland, M, Maitland, ML, Desai, A, Singleton, PA, Sammani, S, Sam, L, Liu, Y, Husain, AN, Lang, RM, Ratain, MJ, Lussier, YA & Garcia, JGN 2008, 'Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension', Physiological Genomics, vol. 33, no. 2, pp. 278-291. https://doi.org/10.1152/physiolgenomics.00169.2007
Moreno-Vinasco, Liliana ; Gomberg-Maitland, Mardi ; Maitland, Michael L. ; Desai, Ankit ; Singleton, Patrick A. ; Sammani, Saad ; Sam, Lee ; Liu, Yang ; Husain, Aliya N. ; Lang, Roberto M. ; Ratain, Mark J. ; Lussier, Yves A ; Garcia, Joe GN. / Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. In: Physiological Genomics. 2008 ; Vol. 33, No. 2. pp. 278-291.
@article{fe42574e0ea0458ab31d55461db570fe,
title = "Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension",
abstract = "Pulmonary hypertension (PH) and cancer pathology share growth factor- and MAPK stress-mediated signaling pathways resulting in endothelial and smooth muscle cell dysfunction and angioproliferative vasculopathy. In this study, we assessed sorafenib, an antineoplastic agent and inhibitor of multiple kinases important in angiogenesis [VEGF receptor (VEGFR)-1-3, PDGF receptor (PDGFR)-β, Raf-1 kinase] as a potential PH therapy. Two PH rat models were used: a conventional hypoxia-induced PH model and an augmented PH model combining dual VEGFR-1 and -2 inhibition (SU-5416, single 20 mg/kg injection) with hypoxia. In addition to normoxia-exposed control animals, four groups were maintained at 10{\%} inspired O2 fraction for 3.5 wk (hypoxia/vehicle, hypoxia/SU-5416, hypoxia/ sorafenib, and hypoxia/SU-5416/sorafenib). Compared with normoxic control animals, rats exposed to hypoxia/SU-5416 developed hemodynamic and histological evidence of severe PH while rats exposed to hypoxia alone displayed only mild elevations in hemodynamic values (pulmonary vascular and right ventricular pressures). Sorafenib treatment (daily gavage, 2.5 mg/kg) prevented hemodynamic changes and demonstrated dramatic attenuation of PH-associated vascular remodeling. Compared with normoxic control rats, expression profiling (Affymetrix platform) of lung RNA obtained from hypoxia [false discovery rate (FDR) 6.5{\%}]- and hypoxia/SU-5416 (FDR 1.6{\%})-challenged rats yielded 1,019 and 465 differentially regulated genes (fold change >1.4), respectively. A novel molecular signature consisting of 38 differentially expressed genes between hypoxia/SU-5416 and hypoxia/SU-5416/sorafenib (FDR 6.7{\%}) was validated by either real-time RT-PCR or immunoblotting. Finally, immunoblotting studies confirmed the upregulation of the MAPK cascade in both PH models, which was abolished by sorafenib. In summary, sorafenib represents a novel potential treatment for severe PH with the MAPK cascade a potential canonical target.",
keywords = "Bioinformatics, Microarrays, SU-5416",
author = "Liliana Moreno-Vinasco and Mardi Gomberg-Maitland and Maitland, {Michael L.} and Ankit Desai and Singleton, {Patrick A.} and Saad Sammani and Lee Sam and Yang Liu and Husain, {Aliya N.} and Lang, {Roberto M.} and Ratain, {Mark J.} and Lussier, {Yves A} and Garcia, {Joe GN}",
year = "2008",
month = "4",
day = "22",
doi = "10.1152/physiolgenomics.00169.2007",
language = "English (US)",
volume = "33",
pages = "278--291",
journal = "Physiological Genomics",
issn = "1094-8341",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension

AU - Moreno-Vinasco, Liliana

AU - Gomberg-Maitland, Mardi

AU - Maitland, Michael L.

AU - Desai, Ankit

AU - Singleton, Patrick A.

AU - Sammani, Saad

AU - Sam, Lee

AU - Liu, Yang

AU - Husain, Aliya N.

AU - Lang, Roberto M.

AU - Ratain, Mark J.

AU - Lussier, Yves A

AU - Garcia, Joe GN

PY - 2008/4/22

Y1 - 2008/4/22

N2 - Pulmonary hypertension (PH) and cancer pathology share growth factor- and MAPK stress-mediated signaling pathways resulting in endothelial and smooth muscle cell dysfunction and angioproliferative vasculopathy. In this study, we assessed sorafenib, an antineoplastic agent and inhibitor of multiple kinases important in angiogenesis [VEGF receptor (VEGFR)-1-3, PDGF receptor (PDGFR)-β, Raf-1 kinase] as a potential PH therapy. Two PH rat models were used: a conventional hypoxia-induced PH model and an augmented PH model combining dual VEGFR-1 and -2 inhibition (SU-5416, single 20 mg/kg injection) with hypoxia. In addition to normoxia-exposed control animals, four groups were maintained at 10% inspired O2 fraction for 3.5 wk (hypoxia/vehicle, hypoxia/SU-5416, hypoxia/ sorafenib, and hypoxia/SU-5416/sorafenib). Compared with normoxic control animals, rats exposed to hypoxia/SU-5416 developed hemodynamic and histological evidence of severe PH while rats exposed to hypoxia alone displayed only mild elevations in hemodynamic values (pulmonary vascular and right ventricular pressures). Sorafenib treatment (daily gavage, 2.5 mg/kg) prevented hemodynamic changes and demonstrated dramatic attenuation of PH-associated vascular remodeling. Compared with normoxic control rats, expression profiling (Affymetrix platform) of lung RNA obtained from hypoxia [false discovery rate (FDR) 6.5%]- and hypoxia/SU-5416 (FDR 1.6%)-challenged rats yielded 1,019 and 465 differentially regulated genes (fold change >1.4), respectively. A novel molecular signature consisting of 38 differentially expressed genes between hypoxia/SU-5416 and hypoxia/SU-5416/sorafenib (FDR 6.7%) was validated by either real-time RT-PCR or immunoblotting. Finally, immunoblotting studies confirmed the upregulation of the MAPK cascade in both PH models, which was abolished by sorafenib. In summary, sorafenib represents a novel potential treatment for severe PH with the MAPK cascade a potential canonical target.

AB - Pulmonary hypertension (PH) and cancer pathology share growth factor- and MAPK stress-mediated signaling pathways resulting in endothelial and smooth muscle cell dysfunction and angioproliferative vasculopathy. In this study, we assessed sorafenib, an antineoplastic agent and inhibitor of multiple kinases important in angiogenesis [VEGF receptor (VEGFR)-1-3, PDGF receptor (PDGFR)-β, Raf-1 kinase] as a potential PH therapy. Two PH rat models were used: a conventional hypoxia-induced PH model and an augmented PH model combining dual VEGFR-1 and -2 inhibition (SU-5416, single 20 mg/kg injection) with hypoxia. In addition to normoxia-exposed control animals, four groups were maintained at 10% inspired O2 fraction for 3.5 wk (hypoxia/vehicle, hypoxia/SU-5416, hypoxia/ sorafenib, and hypoxia/SU-5416/sorafenib). Compared with normoxic control animals, rats exposed to hypoxia/SU-5416 developed hemodynamic and histological evidence of severe PH while rats exposed to hypoxia alone displayed only mild elevations in hemodynamic values (pulmonary vascular and right ventricular pressures). Sorafenib treatment (daily gavage, 2.5 mg/kg) prevented hemodynamic changes and demonstrated dramatic attenuation of PH-associated vascular remodeling. Compared with normoxic control rats, expression profiling (Affymetrix platform) of lung RNA obtained from hypoxia [false discovery rate (FDR) 6.5%]- and hypoxia/SU-5416 (FDR 1.6%)-challenged rats yielded 1,019 and 465 differentially regulated genes (fold change >1.4), respectively. A novel molecular signature consisting of 38 differentially expressed genes between hypoxia/SU-5416 and hypoxia/SU-5416/sorafenib (FDR 6.7%) was validated by either real-time RT-PCR or immunoblotting. Finally, immunoblotting studies confirmed the upregulation of the MAPK cascade in both PH models, which was abolished by sorafenib. In summary, sorafenib represents a novel potential treatment for severe PH with the MAPK cascade a potential canonical target.

KW - Bioinformatics

KW - Microarrays

KW - SU-5416

UR - http://www.scopus.com/inward/record.url?scp=40749109217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749109217&partnerID=8YFLogxK

U2 - 10.1152/physiolgenomics.00169.2007

DO - 10.1152/physiolgenomics.00169.2007

M3 - Article

VL - 33

SP - 278

EP - 291

JO - Physiological Genomics

JF - Physiological Genomics

SN - 1094-8341

IS - 2

ER -